Regulatory FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia FDAThe U.S.NeuroscienceRead full story pharminent April 30, 2026 (Last updated: May 1, 2026) FDA The U.S. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Eligibility for Medicare Savings Programs for Specified Low-Income Medicare Beneficiaries (SLMBs)Next: Two biotechs raise a combined $556M in latest spurt of IPOs Related Stories Regulatory Bayer gets swift review for Kerendia in type 1 diabetes pharminent May 21, 2026 Regulatory Pazdur declines to announce candidacy for vacated FDA commissioner role pharminent May 20, 2026 Regulatory VERTANICAL’s VER-01 gains FDA breakthrough status for low back pain pharminent May 19, 2026
